To better understand how the field is evolving and where it might go next DDN spoke with Jan Jezek, Chief Scientific Officer at Arecor Therapeutics, about the scientific challenges, delivery innovations, and future opportunities surrounding GLP-1 therapies
Inhibition of cysteine uptake by p53 can sensitize cells to ferroptosis through downregulating the expression of SLC7A11 and GPX4, reduction of antioxidant capacity, and resultant ROS accumulation [53, 54]
Clinical trials and other interventions are designed to translate findings from human and experimental investigations to public health prevention
Reduced Inflammation: Helps manage and reduce inflammation, which can contribute to faster recovery times and less discomfort
2 GLP-1 receptor agonists (GLP-1 RAs) as mediators of aging hallmarks
Thats where low-calorie, high-protein foods come in